RSS-Feed abonnieren
DOI: 10.1055/s-0029-1243230
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York
Comparison of Insulin Detemir and Insulin Glargine on Glycemic Variability in Patients with Type 1 and Type 2 Diabetes
Publikationsverlauf
received 07.08.2009
first decision 14.10.2009
accepted 18.11.2009
Publikationsdatum:
12. Januar 2010 (online)

Abstract
Aims: To compare the glycemic variability of insulin detemir and insulin glargine in type 1 and type 2 diabetic patients.
Methods: 15 type 1 and 14 type 2 diabetic patients receiving intensive insulin therapy with insulin glargine were enrolled. Before and after switching insulin glargine to insulin detemir, we assessed fasting glucose variability using the standard deviation (SD) and the coefficient of variance (CV) of self-monitored fasting blood sugar (FBS) levels.
Results: The SD and CV values were significantly decreased in type 1 diabetes after switching the therapy, though there was no significant difference in type 2 diabetes. The frequency of hypoglycemia was decreased in type 1 diabetes and there was no change in type 2 diabetes. The changes of the CV value also showed significant positive correlation with fasting serum CPR levels in all patients and total insulin dose in type 1 diabetes. The changes of frequency of hypoglycemia showed significant positive correlation with total and basal insulin dose adjusted for body weight in type 1 diabetes.
Conclusion: The present study demonstrated lower within-subject variability of insulin detemir compared to insulin glargine, suggesting that the basal insulin replacement with insulin detemir may provide a useful therapeutic strategy for uncontrolled type 1 diabetes with high glucose variability.
Key words
insulin detemir - insulin glargine - hypoglycemia - glycemic variability - diabetes mellitus
References
- 1
Bonds DE, Kurashige EM, Bergenstal R. et al .
Severe hypoglycemia monitoring and risk management procedures in the Action to Control
Cardiovascular Risk in Diabetes (ACCORD) trial.
Am J Cardiol.
2007;
99
80i-89i
MissingFormLabel
- 2
Cefalu WT, Watson K.
Intensive glycemic control and cardiovascular disease observations from the ACCORD
study: now what can a clinician possibly think?.
Diabetes.
2008;
57
1163-1165
MissingFormLabel
- 3
Danne T, Datz N, Endahl L. et al .
Insulin detemir is characterized by a more reproducible pharmacokinetic profile than
insulin glargine in children and adolescents with type 1 diabetes: results from a
randomized, double-blind, controlled trial*.
Pediatr Diabetes.
2008;
9
554-560
MissingFormLabel
- 4
Heise T, Nosek L, Ronn BB. et al .
Lower within-subject variability of insulin detemir in comparison to NPH insulin and
insulin glargine in people with type 1 diabetes.
Diabetes.
2004;
53
1614-1620
MissingFormLabel
- 5
Hermansen K, Davies M, Derezinski T. et al .
A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with
NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people
with type 2 diabetes.
Diabetes Care.
2006;
29
1269-1274
MissingFormLabel
- 6
King AB.
Once-daily insulin detemir is comparable to once-daily insulin glargine in providing
glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized,
crossover study.
Diabetes Obes Metab.
2009;
11
69-71
MissingFormLabel
- 7
Klein O, Lynge J, Endahl L. et al .
Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action
profiles but less variability than insulin glargine in type 2 diabetes.
Diabetes Obes Metab.
2007;
9
290-299
MissingFormLabel
- 8
Kolendorf K, Ross GP, Pavlic-Renar I. et al .
Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma
glucose levels compared with NPH insulin in Type 1 diabetes.
Diabet Med.
2006;
23
729-735
MissingFormLabel
- 9
Meneghini LF, Rosenberg KH, Koenen C. et al .
Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain
in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin
glargine: clinical practice experience from a German subgroup of the PREDICTIVE study.
Diabetes Obes Metab.
2007;
9
418-427
MissingFormLabel
- 10
Moberg EA, Lins PE, Adamson UK.
Variability of blood glucose levels in patients with type 1 diabetes mellitus on intensified
insulin regimens.
Diabete Metab.
1994;
20
546-552
MissingFormLabel
- 11
Muggeo M, Zoppini G, Bonora E. et al .
Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients:
the Verona Diabetes Study.
Diabetes Care.
2000;
23
45-50
MissingFormLabel
- 12
Pieber TR, Treichel HC, Hompesch B. et al .
Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes
using intensive insulin therapy.
Diabet Med.
2007;
24
635-642
MissingFormLabel
- 13
Porcellati F, Rossetti P, Busciantella NR. et al .
Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine
and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover
study.
Diabetes Care.
2007;
30
2447-2452
MissingFormLabel
- 14
Ratner RE, Hirsch IB, Neifing JL. et al .
Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetesU.S.
Study Group of Insulin Glargine in Type 1 Diabetes.
Diabetes Care.
2000;
23
639-643
MissingFormLabel
- 15
Rosenstock J, Davies M, Home PD. et al .
A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin
glargine when administered as add-on to glucose-lowering drugs in insulin-naive people
with type 2 diabetes.
Diabetologia.
2008;
51
408-416
MissingFormLabel
- 16
Vague P, Selam JL, Skeie S. et al .
Insulin detemir is associated with more predictable glycemic control and reduced risk
of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus
regimen with premeal insulin aspart.
Diabetes Care.
2003;
26
590-596
MissingFormLabel
- 17
White NH, Chase HP. et al .
Comparison of glycemic variability associated with insulin glargine and intermediate-acting
insulin when used as the basal component of multiple daily injections for adolescents
with type 1 diabetes.
Diabetes Care.
2009;
32
387-393
MissingFormLabel
Correspondence
A. ToneMD, PhD
Department of Diabetes and Metabolism
National Hospital Organization
Okayama Medical Center
1711-1, Tamasu, Kita-ku
701-1192 Okayama
Japan
Telefon: +81-86-294-9911
Fax: +81-86-294-9255
eMail: aitone@okayama3.hosp.go.jp